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Corticosteroids have been used in combination with chemotherapy for the treatment of metastatic castration-resistant
prostate cancer (mCRPC) for more than three decades, particularly to treat pain, inflammation, and edema. More re-
cently, they have been used in combination with hormonal agents. The importance of corticosteroids in mCRPC is
due to their ability to manage adverse effects, reduce symptoms, and improve patients’ quality of life. The appropriate
selection of available options in mCRPC should be based on careful consideration of a patient’s profile and comorbidities.
This review provides an overview of the role of corticosteroids in treating mCRPC for the practicing urologist. UROLOGY
96: 156–164, 2016. © 2016 The Authors. Published by Elsevier Inc.
Prostate cancer is the most common type of cancerin men in developed countries and the second mostcommon cancer worldwide, with an estimated 1.1
million new cases diagnosed in 2012.1 It is also the fifth
leading cause of death from cancer in men, with an esti-
mated 307,000 deaths in 2012 globally.1 Localized pros-
tate cancer can be treated successfully with surgery,
radiotherapy, or androgen deprivation therapy (ADT), and
ADT plus docetaxel is now the standard treatment for
androgen-sensitive metastatic prostate cancer based on the
results of the recent CHAARTED2 and STAMPEDE
studies.3 However, many men with metastatic prostate
cancer will progress to metastatic castration-resistant pros-
tate cancer (mCRPC),4 which has a poor prognosis
and median overall survival (OS) of 2.5-3 years in
chemotherapy-naïve patients.5,6
For many years, chemotherapy has been the only life-
prolonging therapy available for mCRPC. However, more
recently, several hormonal agents have been approved for
the treatment of mCRPC, such as the oral androgen bio-
synthesis inhibitor abiraterone acetate and the oral androgen
receptor inhibitor enzalutamide, which have been shown to
extend survival in patients who have not yet received
chemotherapy.5,6
Corticosteroids have been used in the treatment of
mCRPC for more than three decades, particularly to treat
pain, inflammation, and edema caused by metastases and
space-occupying lesions,7 to improve the fatigue associ-
ated with the disease and ADT, and as a premedication
for chemotherapy. Corticosteroids have been shown to de-
crease prostate-specific antigen (PSA) levels in retrospec-
tive and prospective clinical studies of men with mCRPC
and chemotherapy-naïve castration-resistant prostate cancer,
respectively.8,9 However, corticosteroid-responsive andro-
gen receptor mutations have been observed, which may con-
tribute to androgen-independent growth in metastatic
tumors.10 Recently, corticosteroids have also been used in
combination with ketoconazole and hormonal agents such
as abiraterone and enzalutamide.
With the availability of the oral life-prolonging hor-
monal therapies, urologists are increasingly managing pa-
tients with more advanced disease, including mCRPC,
highlighting the need for enhanced awareness about the
place and correct use of corticosteroids in therapy. The aim
of this review is to provide an overview for the urologist
of the role of corticosteroids in the treatment of mCRPC
in clinical practice.
CORTICOSTEROID USE IN mCRPC
Rationale
Corticosteroids are commonly used in the treatment of
mCRPC, partly because of their inhibitory effects on the
secretion of adrenocorticotropic hormone (ACTH) and
partly because of their palliative effects. Inhibition of ACTH
results in a number of effects, such as the downregulation
of adrenal androgens, transcription factors, and cytokines.11,12
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The anti-inflammatory properties of prednisone may relieve
the eventual pain caused by metastases.13 In addition, cor-
ticosteroids may have a cytotoxic effect on prostate cancer
cells, mediated in part by the downregulation of andro-
gen receptors and the activation of glucocorticoid receptor-
mediated signaling and downstream antiangiogenic activity,
resulting in a reduction of interleukin-8 and vascular en-
dothelial growth factor.11,12
Palliative Effects of Corticosteroids and Use of
Low-dose Corticosteroids
In general oncology, corticosteroids are frequently used for
different types of pain and palliation in cancer patients14;
however, their beneficial effects have only been prospec-
tively evaluated in a few trials.7,15 The most common non-
specific symptoms that improved with corticosteroid
treatment in a prospective study were anorexia, nausea, pain,
low mood, vomiting, weakness, and general well-being.15
Palliative benefits with low doses of corticosteroids were
usually seen within 5 days of treatment initiation and pain
improvement lasted for several weeks.16 In patients
with mCRPC, pain relief appeared to be associated with
decreased androgen levels.13 This might explain the dis-
tinct success of corticosteroids in the treatment of symp-
tomatic prostate cancer compared to other cancer or sources
of pain. A recent meta-analysis that evaluated the use of
corticosteroids for the management of general cancer-
related pain clearly showed that there was significant relief
of pain (all types and locations) within 1 week of corti-
costeroid treatment initiation.7
In daily practice, the concomitant use of corticoste-
roids with other palliative measures, pain medication, and
anticancer treatments seems to confer the most benefit. In
particular, corticosteroid use within the current armamen-
tarium for the treatment of bone pain has become well
established.15 Although corticosteroids are the most effec-
tive treatment for inflammatory pain, they differ in anti-
inflammatory potency; for example, prednisolone is thrice
and dexamethasone is 26 times as potent as cortisol.17 For
the treatment of prostate cancer, low-dose corticosteroids
are mostly used, with a low dose usually considered to be
prednisone or prednisolone 5-15 mg/day and dexametha-
sone 0.5-3 mg/day.
Low-dose prednisone (7.5-10 mg/day) in mCRPC was
first used in a prospective study that evaluated pain and
quality of life in 37 patients with mCRPC and symptom-
atic bone metastases.13 In 14 (38%) patients, pain symp-
toms were improved, which was maintained for 3-30 months
(median, 4 months) in 7 (19%) patients. The reduction
in pain was associated with an improvement in quality of
life. In a retrospective study of low-dose dexamethasone
(0.75 mg twice or thrice daily) in 36 patients with mCRPC,
most patients experienced symptomatic relief and a de-
crease in PSA levels (Table 1).8 Pain relief and improve-
ments in quality of life have also been shown with
prednisone 5 mg twice daily in combination with either
docetaxel or mitoxantrone plus prednisone in two ran-
domized controlled trials.21,22 T
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In a recent phase 2 study in 82 patients with mCRPC,
dexamethasone 0.5 mg/day was compared with predniso-
lone 5 mg twice daily.9 Pain scores, analgesic use, and the
EuroQoL 5-dimension overall health status scores im-
proved during the study, with no significant difference
between treatments but with a trend for greater improve-
ment in pain management with dexamethasone than with
prednisolone. A confirmed PSA response, which was the
primary end point of this trial, occurred in 41% of
dexamethasone-treated patients vs 22% of prednisolone-
treated patients (P = .08) (Table 1).
In the last few years, the therapeutic landscape for
mCRPC has changed considerably, and low-dose cortico-
steroids are used in combination therapy in a number of
clinical settings beyond palliation, with both chemo-
therapy and some of the hormonal agents now available
for mCRPC, as recommended in several treatment guide-
lines (Table 2).
Corticosteroids Combination Therapy With
Chemotherapeutic Agents
Mitoxantrone plus a corticosteroid (prednisone or hydro-
cortisone) became the reference standard for many trials
after it had been shown to provide an improved pallia-
tive response in symptomatic patients compared with cor-
ticosteroids alone. This combination had been the standard
treatment for mCRPC for many years, albeit without having
a proven OS benefit.27,28 In 2004, chemotherapy with
docetaxel became the standard of care for first-line treat-
ment of mCRPC following the results of two pivotal phase
3 studies (TAX 327 and SWOG 9916), which showed su-
perior OS and a palliative benefit in men with symptom-
atic disease compared to mitoxantrone.21,22 Low-dose
corticosteroids were used in all treatment arms.21,22
Cabazitaxel with daily prednisone is used as second-line
therapy in patients who have previously progressed on
docetaxel, based on the results of an open-label, random-
ized, phase 3 study that used mitoxantrone plus predni-
sone as the control arm.29
Prednisone in combination with chemotherapy in dif-
ferent settings, including first-line treatment, is recom-
mended by guidelines from the American Society of Clinical
Oncology,4 the Canadian Urological Association,24 the Na-
tional Comprehensive Cancer Network,25 and the Euro-
pean Association of Urology26 (Table 2). More recent trials
in patients with early hormone-naïve and asymptomatic
prostate cancer have provided evidence for the efficacy (sig-
nificant improvement in progression-free survival and/or
OS) of docetaxel without any concomitant daily
corticosteroids.2,30
The rationale for adding low-dose corticosteroids to
taxane chemotherapy, based on the historical use of
mitoxantrone and prednisone, is for the management of
symptoms and adverse events (AEs) rather than for im-
proving responses.31 Comparing the results of the TAX 327
study,22 in which patients with castration-resistant prostate
cancer received docetaxel plus prednisone 5 mg twice daily,
with the ASCENT study,32 in which the control group
received docetaxel plus placebo, the incidences of fatigue,
nausea, or vomiting, and peripheral edema, among other
symptoms, were lower in patients who received docetaxel
plus prednisone in the TAX 327 study vs those who re-
ceived docetaxel plus placebo in the ASCENT study. Results
from the STAMPEDE study, in which some patients with
castration-sensitive prostate cancer received treatment with
ADT and docetaxel plus prednisone 10 mg daily, showed
a 10-month increase in median survival compared with
ADT alone.2 This significant increase in survival was similar
to the 13.5-month increase in median survival observed
in patients with castration-sensitive prostate cancer who
received ADT with docetaxel vs ADT alone in the
CHAARTED study.3 In addition, the rate of AEs re-
ported in both studies were similar, with the exception of
a higher rate of neurotropic sepsis in STAMPEDE com-
pared to CHAARTED (12% and 6%, respectively), which
was not attributed to the use of prednisone.2,3 Taken to-
gether, these results indicate that corticosteroid use in this
latter clinical setting does not reduce the efficacy
of docetaxel, nor does it result in an increase in side
effects.
The use of docetaxel requires the administration of dexa-
methasone for the prevention of hypersensitivity reac-
tions and fluid-retention reactions. It is recommended that
dexamethasone 8 mg twice daily is administered for 3 days,
starting the day before docetaxel is administered. In prac-
tice, dexamethasone 8 mg can also be given 12 hours, 3
hours, and 1 hour prior to docetaxel infusion. In prac-
tice, based on our own experiences, docetaxel is used both
with and without prednisone, and docetaxel treatment can
be adapted to add corticosteroid, if needed, to manage
nausea, fatigue, and weight loss.
HORMONAL AGENTS
Corticosteroid Use With Abiraterone
Abiraterone acetate is a small molecule inhibitor of cyto-
chrome P450 c17, a key enzyme in testosterone synthe-
sis, which blocks androgen synthesis by the adrenal glands
and testes and within the prostate tumor.33 Inhibition of
cortisol synthesis is associated with an increase in ACTH
that causes raised mineralocorticoids, leading to AEs such
as fluid overload, hypertension, and hypokalemia.33 A phase
2 study showed that the incidence of mineralocorticoid-
related AEs with abiraterone (eg, hypertension and hypo-
kalemia) was reduced by the addition of low-dose prednisone
(5 mg twice daily).34 The combination of abiraterone plus
prednisone was therefore recommended for phase 3 studies.
Similar to their use with ketoconazole, corticosteroids are
used in this indication to substitute the decreased adre-
nocortical steroid production, the amount of which varies
between individuals. Therefore, the dose of corticoste-
roids required will vary from patient to patient. In daily
practice, corticosteroid doses are frequently adjusted and
reduced to 5 mg daily (based on personal experience).
Ongoing studies are evaluating low-dose corticosteroids with
abiraterone.20,35
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Table 2. Summary of corticosteroid-containing treatment regimens in mCRPC recommended by guidelines
Combination
Guideline
ASCO4 AUA23 CUA24 NCCN25 EAU26
Abiraterone plus
prednisone
In addition to
continued
androgen
deprivation
therapy
• Patients with asymptomatic,
minimally symptomatic, or
symptomatic mCRPC with good
ECOG PS, symptomatic mCRPC
with poor ECOG PS, and no prior
docetaxel chemotherapy
• Patients with mCRPC with good
or poor ECOG PS who received
prior docetaxel chemotherapy
Chemotherapy-naïve
• First-line therapy for
asymptomatic or minimally
symptomatic mCRPC
Post-docetaxel
• Patients progressing on or
after docetaxel-based
chemotherapy
• First-line therapy for patients with
asymptomatic, chemotherapy-
naïve mCRPC
• Patients with mCRPC after
docetaxel failure, provided not
used before docetaxel
• Prednisone/prednisolone
(2 × 5 mg) must be used
when abiraterone is used
in CRPC to prevent induced
hyperaldosteronism
Docetaxel plus
prednisone
In addition to
continued
androgen
deprivation
therapy
— First-line systemic
chemotherapy for patients
with mCRPC
• Traditional mainstay of treatment
for symptomatic metastases
• Docetaxel is not used commonly
for asymptomatic patients but may
be considered when a patient
shows signs of rapid progression
or visceral metastases despite
lack of symptoms
• Docetaxel plus prednisone every
3 weeks is the preferred first-line
chemotherapy treatment for
symptomatic CRPC with visceral
metastases
• For patients with disease
progression after enzalutamide or
abiraterone
Cabazitaxel plus
prednisone
For patients who
experience
progression
with docetaxel
— Patients with mCRPC who
have progressed after
docetaxel-based
chemotherapy
Patients with mCRPC after docetaxel
failure
Continued
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Table 2. Continued
Combination
Guideline
ASCO4 AUA23 CUA24 NCCN25 EAU26
Mitoxantrone plus
prednisone
— — Alternative first-line systemic
chemotherapy for patients
with mCRPC that has not
demonstrated improvement
in overall survival but can
provide disease control and
palliation and improve
quality of life
—
Ketoconazole plus
corticosteroids
— • Patients with asymptomatic,
minimally symptomatic, or
symptomatic mCRPC with
good ECOG PS and no prior
docetaxel chemotherapy who
do not want or cannot have
standard therapy
• Patients with symptomatic
mCRPC with poor ECOG PS
and no prior docetaxel
chemotherapy who are unable
or unwilling to receive
abiraterone plus prednisone or
enzalutamide
• Patients with mCRPC with
good ECOG PS who received
prior docetaxel if abiraterone
plus prednisone, cabazitaxel,
or enzalutamide is unavailable
• Patients with mCRPC with poor
ECOG PS who received prior
docetaxel chemotherapy
mCRPC without symptoms or
minimally symptomatic
—
ASCO, American Society of Clinical Oncology; AUA, American Urological Association; CUA, Canadian Urological Association; EAU, European Association of Urology; ECOG PS, Eastern Cooperative
Oncology Group performance status; mCRPC, metastatic castration-resistant prostate cancer; NCCN, National Comprehensive Cancer Network.
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The phase 2 IMAAGEN study investigated the use of
reduced-dose prednisone 5 mg/day in combination with
abiraterone 1000 mg/day in patients with nonmetastatic
castration-resistant prostate cancer and increasing PSA
levels.20,35 The combination was very effective in lower-
ing PSA (Table 1),20 and its safety profile was similar to
that of abiraterone plus prednisone 10 mg/day.35 Another
study (NCT01867710) is investigating abiraterone in com-
bination with different corticosteroid regimens (predni-
sone 2.5 mg twice daily, prednisone 5 mg once and twice
daily, and dexamethasone 0.5 mg once daily) for the re-
duction of AEs.
Abiraterone with prednisone or prednisolone is indi-
cated for the treatment of mCRPC in patients who are
chemotherapy-naïve, as well as those whose disease has pro-
gressed on or after a docetaxel-based chemotherapy regimen.
The approval of abiraterone plus prednisone was based on
the results of two pivotal placebo-controlled, double-
blind, randomized, phase 3 studies: COU-AA-302 in
chemotherapy-naïve patients6,19 and COU-AA-301 in pa-
tients who had progressed on docetaxel chemotherapy.18 In
both studies, patients received either abiraterone 1000 mg
once daily plus prednisone 5 mg twice daily or placebo plus
prednisone 5 mg twice daily. Abiraterone plus prednisone
significantly prolongedOS vs prednisone alone in both studies
and is recommended by guidelines from theAmerican Society
of Clinical Oncology,4 theAmericanUrological Association,23
the Canadian Urological Association,24 and the National
Comprehensive Cancer Network25 (Table 2). A recent post
hoc analysis from the COU-AA-301 study assessed the as-
sociation of OS with baseline corticosteroid use. Whereas
a univariate model showed that baseline corticosteroid use
was associated with patients having worse disease charac-
teristics, a multivariate model showed that baseline corti-
costeroid use did not adversely impact the clinical benefit
of treatment with abiraterone plus prednisone.36
Corticosteroid Use With Enzalutamide
Enzalutamide is an oral, nonsteroidal androgen receptor in-
hibitor that blocks several steps in the androgen receptor
signaling pathway, such as nuclear translocation of the
androgen receptor, DNA binding, and co-activator
recruitment.37 Enzalutamide is indicated for the treat-
ment of adult men with mCRPC who are asymptomatic
or mildly symptomatic after failure of ADT in whom che-
motherapy is not yet clinically indicated, and for the treat-
ment of adult men with mCRPC whose disease has
progressed on or after docetaxel therapy. The approval of
enzalutamide was based on the results of two pivotal ran-
domized, placebo-controlled, phase 3 studies; one in
chemotherapy-naïve patients (PREVAIL)5 and one in pa-
tients who had received prior docetaxel (AFFIRM).38 In
both studies, enzalutamide was administered orally at a dose
of 160 mg/day and patients were allowed, but not required,
to take prednisone or other corticosteroids (maximum daily
dose, prednisone 10 mg or equivalent).
Enzalutamide does not require co-administration of a cor-
ticosteroid. In the AFFIRM study, approximately 30% of
enzalutamide patients were receiving corticosteroids at base-
line and approximately half of these patients remained on
corticosteroids throughout the study.39,40 In the PREVAIL
study, only 4% of patients were receiving corticosteroids
at study entry.5 In two post hoc analyses of the AFFIRM
study, the association of baseline40 and on-study39 cortico-
steroid use with outcomes was investigated. Baseline cor-
ticosteroid use was associated with reduced OS in both
enzalutamide and placebo groups in a multivariate model,
with enzalutamide being consistently superior to placebo
in terms of OS, radiographical progression-free survival, and
time to PSA progression, irrespective of baseline cortico-
steroid use.40 Similar results were obtained in a secondary
analysis looking at on-study corticosteroid use.39 In addi-
tion, the improved outcomes with enzalutamide over
placebo in patient-reported outcomes in the AFFIRM study
were observed with or without corticosteroid use at
baseline.41 The authors speculated that inferior outcomes
observed in patients with corticosteroid use at baseline or
during that study may have been due to unmeasured con-
founders or the biological properties of corticosteroids.39
The differences in disease severity at baseline (ie, more ad-
vanced disease in corticosteroid vs noncorticosteroid use
subpopulations) also cannot be excluded.39
If patients are receiving corticosteroids, this does not pre-
clude the use of enzalutamide. If a clinician chooses to use
corticosteroids with enzalutamide, this should be accord-
ing to the clinical need (eg, palliation of symptoms). Use
of corticosteroids without a clear clinical rationale should
be discouraged due to the proposed mechanisms in which
corticosteroids may confer resistance to enzalutamide. One
proposed mechanism involves corticosteroids outcompet-
ing enzalutamide for binding of androgen receptor target
genes in tumor cells that express an androgen receptor car-
rying the ARL702H mutation. Another proposed mecha-
nism involves bypassing enzalutamide’s blockade of androgen
receptor target gene expression by directly activating the
glucocorticoid receptor that is acquired by tumor cells.42
IMMUNOTHERAPY
Corticosteroid Use With Immunotherapy
Sipuleucel-T is an autologous cellular immunotherapy that
is indicated for the treatment of asymptomatic or mini-
mally symptomatic mCRPC, based on the results of three
randomized, double-blind, placebo-controlled, phase 3
studies.43 It is available in the USA, but in Europe its mar-
keting authorization was withdrawn in May 2015. Because
of the potential immunosuppressive effects of corticoste-
roids, their use with sipuleucel-T should be reduced or dis-
continued (according to the manufacturer). Based on the
phase 3 IMPACT study, corticosteroid use should be avoided
within 28 days prior to treatment with sipuleucel-T and
resumed following disease progression (median time to
progression was 14.6 weeks).44 However, in a recent phase
2 study by Small et al, concurrent or sequential
administration of sipuleucel-T with abiraterone plus pred-
nisone in patients with mCRPC resulted in sipuleucel-T
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parameter profiles and immunological responses compa-
rable to those observed in the previous phase 3 IMPACT
study. The combination of sipuleucel-T with abiraterone
plus prednisone was also well tolerated.45
CORTICOSTEROID-RELATED ADVERSE
EVENTS AND THEIR MANAGEMENT
Due to potential AEs, the lowest effective corticosteroid
dose should be chosen for long-term use. This does not apply
to short-term use where high doses should provide maximum
effect and immediate symptom relief. Indications for cor-
ticosteroids in prostate cancer are mostly clear cut and are
either high-dose, short-term use for spinal cord compres-
sion or pain exacerbation, usually together with radio-
therapy, or low-dose, long-term use as part of the anticancer
treatment, chronic pain medication, or for improvement
of quality of life/well-being. The use of corticosteroids should
follow the general principle in medicine that the benefits
of treatment need to be weighed against the potential AEs.
The routine monitoring of patients with mCRPC should
enable the safe use of corticosteroids. Comorbidities in pa-
tients with mCRPC that are sensitive to corticosteroids
include diabetes, hypertension, and hyperlipidemia. Such
comorbidities should be taken into account when select-
ing and monitoring treatment. Immediate AEs associated
mainly with intermediate- and high-dose corticosteroids
include immunosuppression, hyperglycemia, and psychi-
atric disorders.46 A frequently reported consequence of im-
munosuppression with corticosteroids is oral candidiasis,
which can usually be effectively treated with local anti-
fungal therapies. Both short- and long-term corticoste-
roid use can result in proximal myopathy.
Corticosteroids are mostly used in patients with pros-
tate cancer who have received long-term ADT, which is
associated with a number of metabolic and bone-related
AEs, such as increased fat mass, decreased lean muscle mass,
and loss of bone mineral density, and can increase the risk
of metabolic and cardiovascular diseases.47 The potential
benefits of corticosteroid use in patients who have re-
ceived long-term ADT should be weighed against the po-
tential risks, in particular in those patients with
comorbidities such as diabetes and hyperglycemia, because
of their potential to aggravate hyperglycemia or hyperten-
sion; careful monitoring of these patients (eg, monthly blood
pressure measurements, etc) is recommended.25 In a study
by Venkitaraman et al,9 clinically relevant AEs with cor-
ticosteroid monotherapy (either prednisolone 10 mg daily
or dexamethasone 0.5 mg daily) were uncommon. However,
14 of 25 patients receiving dexamethasone and 20 of 26
patients receiving prednisolone had at least one glucose
measurement >6 mmol/L. The results of this study thus
support the need for regular monitoring of blood sugar levels.
Corticosteroid-related Adverse Events
Although corticosteroids are typically used at low doses in
mCRPC, they are used for prolonged periods and the
risk of corticosteroid-related AEs rises with increasing
corticosteroid exposure.31 There are limited data on
corticosteroid-related AEs in men with mCRPC, which
include dyspnea, edema, myopathy or muscle loss, hyper-
glycemia or diabetes, and posterior subcapsular cataracts;
these AEs must be weighed against the benefit.18,48
Long-term Corticosteroid Use
Myopathy due to long-term corticosteroid use may aggra-
vate the fatigue caused by mCRPC, chemotherapy, and
ADT, and reduce patients’ quality of life.22,49 The long-
term use of corticosteroids may result in immune suppres-
sion and steroid dependency, which are mainly caused by
disruption of the hypothalamic–pituitary–adrenal axis,50 but
neither have been systematically studied in patients with
cancer. Abrupt withdrawal of corticosteroids after long-
term use, even with low doses, can lead to steroid with-
drawal syndrome, the symptoms of which include weight
loss, nausea, vomiting, myalgia, arthralgia, asthenia, pos-
tural hypotension, tachycardia, and fever.
Adrenal insufficiency, secondary to negative feedback of
the hypothalamic–pituitary–adrenal axis following
withdrawal of long-term intermediate and high cortico-
steroid doses, is a rare occurrence and mostly found in dis-
eases other than cancer.50 The symptoms of chronic adrenal
insufficiency include anorexia, weight loss, nausea, vom-
iting, abdominal pain, weakness, fatigue, asthenia, pros-
tration,myalgia, arthralgia, postural hypotension, drowsiness,
depression, andhypoglycemia.50 Some severe cases of chronic
adrenal insufficiency can present with acute adrenal crisis,
symptoms of which include vomiting, diarrhea, fever or hy-
pothermia, acute dehydration, hypotension, hypoglyce-
mia, shock, and coma.50 To prevent the occurrence of
corticosteroid withdrawal symptoms, the corticosteroid dose
should be gradually reduced. Steroid dependency is usually
seen in patients treated with high-dose corticosteroids, but
it can also occur in patients on long-term low-dose corti-
costeroids. Although uncommon in mCRPC, the poten-
tial for corticosteroid dependency and the possible need
for gradual withdrawal if corticosteroid therapy has to be
discontinued should be recognized. There are no guide-
lines on dose reduction for corticosteroid withdrawal;
however, a practical approach is to reduce the dose by half
per week, for example, prednisone 10 to 5 mg/day in week
1, 5 to 2.5 mg/day in week 2, and then 2.5 mg/day every 2
days during week 3 to stop over a 3-week period (Fig. 1A)
or step-wise reduction in dosage, depending on the start-
ing dose (Fig. 1B). Ongoing steroid dependency is usually
seen in patients treated with high-dose corticosteroids and
is rarely seen with long-term, low-dose corticosteroids. In
such a case, referral of the patient to an endocrinologist
might be indicated.
CONCLUSION
Corticosteroids play an important role in the treatment of
mCRPC as a result of their ability to manage the AEs as-
sociated with certain prostate cancer therapies, reduce
symptoms, and improve patients’ quality of life. Effective
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management of potential long-term corticosteroid-related
AEs and effects on tumor biology can be achieved with the
appropriate selection of available therapeutic options in
mCRPC, based on the careful consideration of a pa-
tient’s profile and comorbidities.
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